医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Final Results

Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks

Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks

バイオテクノロジーヘルスケア医療機器臨床試験製薬　 TimeLine: Final Results Injection for Long-Term Prevention of Hereditary Angioedema Attacks lanadelumab

2021年08月05日

Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema

Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema

その他ヘルスバイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: Final Results HELP Study Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema lanadelumab-flyo Open-Label Extension Support TAKHZYRO

2020年11月13日